Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 8212

Original article / research
Year : 2017 | Month : September | Volume : 11 | Issue : 9 | Page : EC01 - EC04

Role of HER-2/neu in Premalignant and Malignant Lesions of Uterine Cervix

Swasti Bajpai, Seema Awasthi, Shyamoli Dutta, Ankita Mittal, Ashutosh Kumar, Faiyaz Ahmad

1. Postgraduate Student, Department of Pathology, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India. 2. Professor, Department of Pathology, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India. 3. Professor and Head, Department of Pathology, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India. 4. Assistant Professor, Department of Pathology, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India. 5. Assistant Professor, Department of Pathology, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India. 6. Assistant Professor, Department of Pathology, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India.

Correspondence Address :
Dr. Seema Awasthi,
Professor, Faculty Block-B, 201, Teerthanker Mahaveer University Campus, Moradabad-244001, Uttar Pradesh, India.
E-mail: dr.seemaabhishek@yahoo.com

Abstract

Introduction: In light of literature and controversy that exists in various cervical lesions, this prospective study was designed to explore the expression of Human Epidermal Growth Factor Receptor-2 (HER-2/neu) in the cervical lesions and its correlation with the histopathological grade and type of tumour. Immunohistochemistry (IHC) was performed to evaluate HER-2/neu expression as it is the most reliable method of detecting overexpression of HER-2/neu.

Aim: To assess the role of HER-2/neu expression in premalignant and malignant lesions of uterine cervix.

Materials and Methods: Seventy cases of premalignant and malignant cervical lesions received in our department from January 2015 to December 2016, were included in study and Polyclonal Rabbit Anti-Human c-erbB-2 oncoprotein from DAKO was used. Standard streptovidin-biotin peroxidase method of IHC was followed. A golden brown membrane and cytoplasmic staining was taken as a positive reaction and intensity of expression was graded according to the 2014 ASCO/CAP guidelines for HER-2/neu reporting.

Results: Out of total 70 cases, HER-2/neu expression scores were 0 in 64.3% {23 cases of Cervical Intraepithelial Neoplasia (CIN) and 22 of Squamous Cell Carcinoma (SCC)}, +1 in 22.9%, (04 cases of CIN and 12 of SCC) +2 in 10% (06 cases of SCC and 01 of adenosquamous carcinoma) and +3 in 2.9% (02 cases of adenocarcinoma) cases. HER-2/neu overexpression rate was significantly higher in malignant (48.8%) as compared to pre malignant (14.8%) cases (p=0.004) and expression scores were higher (+2 and +3) in 20.9% of malignant cases as compared to none of pre malignant cases (p=0.020). Significant higher HER-2/neu scores are seen (+2 and +3) in all the adenocarcinoma cases as compared to 15% cases of SCC (p<0.001). Among malignant cases, HER-2/neu expression was statistically significantly higher in {Moderately Differentiated (MD) + Poorly Differentiated (PD)} 59.09% as compared to {Well Differentiated (WD)} 38.09% cases (p=0.090).

Conclusion: Study shows that expression of HER-2/neu is relatively lower in cervical lesions. However, the results of our study show that with shift from well to poorly differentiated lesions; the HER-2/neu expression rate shows an incremental trend.

Keywords

Cervical carcinoma , Immunohistochemistry, Oncoprotein, Overexpression

How to cite this article :

Swasti Bajpai, Seema Awasthi, Shyamoli Dutta, Ankita Mittal, Ashutosh Kumar, Faiyaz Ahmad. ROLE OF HER-2/NEU IN PREMALIGNANT AND MALIGNANT LESIONS OF UTERINE CERVIX. Journal of Clinical and Diagnostic Research [serial online] 2017 September [cited: 2017 Nov 20 ]; 11:EC01-EC04. Available from
http://www.jcdr.net/back_issues.asp?issn=0973-709x&year=2017&month=September&volume=11&issue=9&page=EC01-EC04&id=10547

DOI and Others

DOI: 10.7860/JCDR/2017/26583.10547

Date of Submission: Jan 05, 2017
Date of Peer Review: Feb 13, 2017
Date of Acceptance: May 31, 2017
Date of Publishing: Sep 01, 2017

FINANCIAl OR OTHER COMPETING INTERESTS: None.

JCDR is now Monthly and more widely Indexed .
  • PubMed Central® (PMC)New
  • Academic Search Complete Database
  • Chemical Abstracts Service
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhostNew
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Open J-Gate
  • Popline (reproductive health literature)
  • SCOPUS
  • www.omnimedicalsearch.com